Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea
Conditions
Interventions
CD07805/47 gel 0.5%
Locations
27
United States
The Laser Institute for Dermatology
Santa Monica, California, United States
Cherry Creek Research, Inc
Denver, Colorado, United States
Longmont Clinical PC
Longmont, Colorado, United States
Gwinnett Clinical Research Center, Inc
Snellville, Georgia, United States
Deaconess Clinic
Evansville, Indiana, United States
Compliant Clinical Research
Olathe, Kansas, United States
Start Date
March 1, 2011
Primary Completion Date
June 1, 2012
Completion Date
July 1, 2012
Last Updated
February 18, 2021
NCT07106957
NCT06466018
NCT04108897
NCT07250165
NCT04214483
NCT06915636
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions